Acorda Therapeutics, Inc. news

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, MD, President and CEO, will present at the H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10 – 13, 2022.

H.C. Wainwright BIOCONNECT Conference
Date: January 10 – 13, 2022
Presentation Time: Available on-demand January 10, 2022 at 7:00 am ET
Webcast: 

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA^® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.⁽¹⁾

Under the terms of the distribution and supply

Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Biopas Laboratories today announced that they have entered into distribution and supply agreements to commercialize INBRIJA in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson`s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.

Under the terms of the agreements, Acorda will receive a significant

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that John Varian has joined its board of directors, effective January 1, 2022.

“We are delighted that John has joined Acorda’s board of directors,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. “We expect his insights and counsel to contribute significantly as we continue to make progress on our corporate goals, including optimizing the company’s financial structure and